43.96 USD
-1.48 (-3.26%)
43.96 USD
0 (0%)
Taking everything into account, EXEL scores 8 out of 10 in our fundamental rating. EXEL was compared to 529 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. EXEL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make EXEL a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
- In the past year EXEL was profitable.
- EXEL had a positive operating cash flow in the past year.
- In the past 5 years EXEL has always been profitable.
- In the past 5 years EXEL always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 24.01%, EXEL belongs to the top of the industry, outperforming 97.54% of the companies in the same industry.
- The Return On Equity of EXEL (31.37%) is better than 97.73% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 26.31%, EXEL belongs to the top of the industry, outperforming 98.86% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for EXEL is significantly below the industry average of 18.28%.
- The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(26.31%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROIC | 26.31% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
- EXEL's Profit Margin of 29.63% is amongst the best of the industry. EXEL outperforms 95.64% of its industry peers.
- In the last couple of years the Profit Margin of EXEL has declined.
- Looking at the Operating Margin, with a value of 35.85%, EXEL belongs to the top of the industry, outperforming 97.54% of the companies in the same industry.
- EXEL's Operating Margin has declined in the last couple of years.
- With an excellent Gross Margin value of 96.63%, EXEL belongs to the best of the industry, outperforming 96.59% of the companies in the same industry.
- EXEL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
- EXEL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, EXEL has less shares outstanding
- Compared to 5 years ago, EXEL has less shares outstanding
- There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- EXEL has an Altman-Z score of 12.82. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
- EXEL has a better Altman-Z score (12.82) than 85.04% of its industry peers.
- EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.82 |
ROIC/WACC2.96
WACC8.88%
2.3 Liquidity
- A Current Ratio of 3.75 indicates that EXEL has no problem at all paying its short term obligations.
- EXEL has a Current ratio (3.75) which is in line with its industry peers.
- A Quick Ratio of 3.68 indicates that EXEL has no problem at all paying its short term obligations.
- EXEL's Quick ratio of 3.68 is in line compared to the rest of the industry. EXEL outperforms 46.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 |
3. Growth
3.1 Past
- EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
- Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
- The Revenue has grown by 9.93% in the past year. This is quite good.
- The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
3.2 Future
- Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 25.68% on average per year.
- EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.99% yearly.
EPS Next Y44.91%
EPS Next 2Y30.69%
EPS Next 3Y29.97%
EPS Next 5Y25.68%
Revenue Next Year7.79%
Revenue Next 2Y10.01%
Revenue Next 3Y11.49%
Revenue Next 5Y9.99%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 18.55, the valuation of EXEL can be described as rather expensive.
- Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 94.70% of the companies are valued more expensively.
- EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.47.
- EXEL is valuated correctly with a Price/Forward Earnings ratio of 13.91.
- 96.21% of the companies in the same industry are more expensive than EXEL, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of EXEL to the average of the S&P500 Index (24.26), we can say EXEL is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.55 | ||
| Fwd PE | 13.91 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 96.02% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, EXEL is valued cheaply inside the industry as 96.78% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.11 | ||
| EV/EBITDA | 11.98 |
4.3 Compensation for Growth
- EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
- EXEL's earnings are expected to grow with 29.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.41
PEG (5Y)1.47
EPS Next 2Y30.69%
EPS Next 3Y29.97%
5. Dividend
5.1 Amount
- EXEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
43.96
-1.48 (-3.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-11 2026-01-11/amc
Earnings (Next)05-11 2026-05-11/amc
Inst Owners97.46%
Inst Owner Change-0.19%
Ins Owners2.18%
Ins Owner Change-2.56%
Market Cap11.79B
Revenue(TTM)2.29B
Net Income(TTM)677.90M
Analysts76.3
Price Target46.24 (5.19%)
Short Float %8.71%
Short Ratio7.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)0.74%
PT rev (3m)2.3%
EPS NQ rev (1m)1.89%
EPS NQ rev (3m)25.71%
EPS NY rev (1m)3.67%
EPS NY rev (3m)10.88%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.55 | ||
| Fwd PE | 13.91 | ||
| P/S | 5.15 | ||
| P/FCF | 15.11 | ||
| P/OCF | 14.9 | ||
| P/B | 5.45 | ||
| P/tB | 5.62 | ||
| EV/EBITDA | 11.98 |
EPS(TTM)2.37
EY5.39%
EPS(NY)3.16
Fwd EY7.19%
FCF(TTM)2.91
FCFY6.62%
OCF(TTM)2.95
OCFY6.71%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.41
PEG (5Y)1.47
Graham Number20.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.01% | ||
| ROE | 31.37% | ||
| ROCE | 33.48% | ||
| ROIC | 26.31% | ||
| ROICexc | 44.11% | ||
| ROICexgc | 46.12% | ||
| OM | 35.85% | ||
| PM (TTM) | 29.63% | ||
| GM | 96.63% | ||
| FCFM | 34.08% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 37.81% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.06% | ||
| Profit Quality | 115.03% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.68 | ||
| Altman-Z | 12.82 |
F-Score8
WACC8.88%
ROIC/WACC2.96
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%72.5%
EPS Next Y44.91%
EPS Next 2Y30.69%
EPS Next 3Y29.97%
EPS Next 5Y25.68%
Revenue 1Y (TTM)9.93%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%10.79%
Revenue Next Year7.79%
Revenue Next 2Y10.01%
Revenue Next 3Y11.49%
Revenue Next 5Y9.99%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year54.05%
EBIT Next 3Y25.06%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
Can you provide the valuation status for EXELIXIS INC?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
Can you provide the profitability details for EXELIXIS INC?
EXELIXIS INC (EXEL) has a profitability rating of 8 / 10.
Can you provide the financial health for EXEL stock?
The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.
What is the expected EPS growth for EXELIXIS INC (EXEL) stock?
The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 44.91% in the next year.